Henri B. Kagan: the chemist whose work helps control molecular handedness

The problem of molecular handedness

Many molecules exist in two mirror-image forms, known as enantiomers. Although their atoms are connected in the same order, the three-dimensional arrangement can affect how a molecule behaves, including in biological systems.

Henri B. Kagan’s research helped establish practical approaches to asymmetric catalysis: using a catalyst to favour the formation of one enantiomer over the other. The 2026 Nobel Prize in Chemistry recognised Kagan jointly with Kenso Soai for foundational advances in this area.

Why chemists care

Controlling molecular handedness is important in pharmaceutical chemistry because different enantiomers can have different biological effects. Catalytic methods can make synthesis more selective and reduce the need to separate mixtures after a reaction.

Kagan’s work sits within a long research field that combines reaction design, catalyst behaviour and careful measurement. A Nobel announcement recognises the contribution to chemistry; it does not mean every drug is made using one specific method.

What the prize does and does not mean

The award recognises a scientific contribution that opened routes for controlling molecular form. It should not be simplified into a claim that one person invented all asymmetric catalysis or that a single reaction solves every synthesis problem.

This profile uses the award announcement and independent science reporting. Details about a particular application should be supported by the corresponding chemical or pharmaceutical evidence.

Editorial disclosure

This article was researched and published with AI assistance. No human prepublication review is claimed. Report factual errors through our contact page.